Replimune Group, Inc.

Equities

REPL

US76029N1063

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 15/07/2024 BST 5-day change 1st Jan Change
10.81 USD +4.34% Intraday chart for Replimune Group, Inc. +28.08% +28.23%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Replimune Group, Inc.(NasdaqGS:REPL) dropped from S&P Biotechnology Select Industry Index CI
Replimune Group Signs $100 Million PIPE Deal with Institutional Investors MT
Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding CI
Transcript : Replimune Group, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:00 PM
HC Wainwright Adjusts Price Target on Replimune to $17 From $12, Maintains Buy Rating MT
Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT
Sector Update: Health Care MT
Replimune Shares Rise as Study Data on Melanoma Treatment Improves MT
Transcript : Replimune Group, Inc. - Special Call
Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma CI
Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology Annual Meeting CI
Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Replimune Group Provides Interim Results for Skin Cancer Therapy MT
Replimune Group, Inc. Announces Management Changes CI
Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024 CI
Transcript : Replimune Group, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 10:45 AM
Wedbush Raises Replimune Group's PT to $16 From $14 After Adjusting Financing Assumptions, Keeps Outperform Rating MT
Replimune Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Transcript : Replimune Group, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 11:15 AM
Wedbush Cuts Replimune Group's PT to $14 From $52 After Narrow Complete Response Rate Miss in Phase 2 Trial of Skin Cancer Treatment Candidate; Keeps Outperform Rating MT
Barclays Lowers Price Target on Replimune Group to $13 From $50, Keeps Overweight Rating MT
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sector Update: Health Care MT
Replimune Group Shares Slide as Trial of Skin Cancer Treatment Candidate Failed to Meet Primary Endpoints MT
Transcript : Replimune Group, Inc. - Special Call
Chart Replimune Group, Inc.
More charts
Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
10.81 USD
Average target price
14.33 USD
Spread / Average Target
+32.59%
Consensus
  1. Stock Market
  2. Equities
  3. REPL Stock
  4. News Replimune Group, Inc.
  5. Sector Update: Health Care Stocks Higher in Late Afternoon Trading